S

Sosei Group Corp
TSE:4565

Watchlist Manager
Sosei Group Corp
TSE:4565
Watchlist
Price: 1 033 JPY 1.08% Market Closed
Market Cap: 92.9B JPY
Have any thoughts about
Sosei Group Corp?
Write Note

Sosei Group Corp
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sosei Group Corp
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
S
Sosei Group Corp
TSE:4565
Additional Paid In Capital
ÂĄ34.7B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
16%
Takeda Pharmaceutical Co Ltd
TSE:4502
Additional Paid In Capital
ÂĄ1.7T
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
41%
Daiichi Sankyo Co Ltd
TSE:4568
Additional Paid In Capital
ÂĄ4B
CAGR 3-Years
N/A
CAGR 5-Years
-47%
CAGR 10-Years
-28%
Otsuka Holdings Co Ltd
TSE:4578
Additional Paid In Capital
ÂĄ504.5B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Chugai Pharmaceutical Co Ltd
TSE:4519
Additional Paid In Capital
ÂĄ69.5B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
0%
Astellas Pharma Inc
TSE:4503
Additional Paid In Capital
ÂĄ183.5B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
0%
No Stocks Found

Sosei Group Corp
Glance View

Market Cap
92.9B JPY
Industry
Pharmaceuticals

Sosei Group Corp. engages in the discovery, design, and development of medicines targeting G protein-coupled receptors (GPCRs). The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 198 full-time employees. The company went IPO on 2004-07-29. The pharmaceutical business is engaged in the research, development and sales of medicines, the management of regenerative medical funds, the investment in bio venture companies related to regenerative medicine, the overseas development by licensing, the promotion of commercialization, the structural analysis of GPCR, the initial lead compound creation, the candidate search by proprietary StaR technology, as well as structural base of new drugs using GPCR related basic technology drug discovery, screening, promotion of antibody drug research and development.

Intrinsic Value
1 330.98 JPY
Undervaluation 22%
Intrinsic Value
Price
S

See Also

What is Sosei Group Corp's Additional Paid In Capital?
Additional Paid In Capital
34.7B JPY

Based on the financial report for Sep 30, 2024, Sosei Group Corp's Additional Paid In Capital amounts to 34.7B JPY.

What is Sosei Group Corp's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
16%

Over the last year, the Additional Paid In Capital growth was 17%. The average annual Additional Paid In Capital growth rates for Sosei Group Corp have been 6% over the past three years , 6% over the past five years , and 16% over the past ten years .

Back to Top